Member Info for LeMajor

Flt3 was low priority and gathering dust. Chinese outfit paid £50k for a chunk of the action if they could crack the problem. They did not, so they relinquish their hold. Back where we were a year ago, but with that £50k in the bank. Hey ho.

If this news is due "mid-January" as previously suggested, todays RNS was indeed timely.

How come it was announced on ASX and not on AIM?

Absolutely. So much rose tinting as to almost block out the sun completely.

It could spike up to that level this week, if milestone payment is forthcoming - though it will probably retrace back to 7.5-10p assuming that RNS is not rapidly followed by a T/O deal.

I suspect PB is chuckling on his cloud at the praise afforded him - considering it was XCD and DW who identified and organised this project while Baz was attending harp lessons. Besides, as far as I'm aware Bazinski was a shale expert, and Peregrine is a conventional play. I'm sure he would be only too pleased though, as any success will pave the way for further attempts to prove up his Icewine play
Best wishes to all for 2021, especially for March results.

With only one and a half trading days in 2020, time to buy sub 3p is short. Although SAR often releases news within an hour of noon, I think it would be unlikely that an RNS will hit Thursday - so with only 1 full trading day this week, I think the awaited RNS will hit us between Monday and Thursday next week. A draft RNS probably exists already, but the guys are probably waiting on a bank draft to hit the account. Hoping to benefit from a 6-9p spike, but the bulk will stay for a BO later in the year. Jettison those vulnerable stop losses and hold tight.

More likely someone got wind of an 11th hour RNS in the pipeline - but content just confirmed AGM results. Things will start to roll in Feb, once transport is under way.

Although thrre was a bit of fanfare when "Will Shakespear" got vaccinated last week, remember that over 100,000 volunteers participated in trials by the 3 -4 main vaccine producers before the TV journalists got involved - THEY were the guinea pigs. Thanks guys!

Convinced I had covid19 between Christmas & new year - fever, chills & 7 weeks of coughing causing aching ribs. Can drop off to sleep for 2-3 hours at drop of a hat - would do a couple of hours in the garden, nothing too strenuous, come indoors for a cuppa and a digestive and wham! - 2 hours in the land of nod. Cannot sleep at night for more than a couple or three hours at a stretch either (like tonight) - my covid antibodies are a year old in a couple of weeks - unfortunately as they drop off rapidly after 4-5 months, probably not detectable/testable any longer apart from long covid lethargy. Wife went into Tesco 2 weeks ago, left me to check my shares via smartphone - she came back 20 mins later nearly gave me a heart attack by knocking on my door - I was away with the fairies. Seems fairly harmless in my case but serious long term organ damage is to be avoided, I just hope Sareum can prove up this treatment so that GP's can shoot first to prevent the damage, then follow through with a vaccine once they both become standard issue off the shelves.

Was there any sort of quid pro quo for the $20m reduction by Sierra? Such as a reduction in the peyiod of exclusivity.

Could this be a simple re-registering of title ? I'm unsure of the devious nature of MMs, but for instance an owner of 60m shares on ASX relocate them to AIM?

All contributes to a bumper H2.

MMs will probably ease it up by 5+% for a few days, then kick off a tree shake before November figures are published (Fri?) I hope DKL have benefitted from the current spike in CPO prices - if so the new nutcracker will be paid for before it goes operational.

Apart from deployment of grant money, is any other striking/spiking news due this side of Christmas?

There are two main approaches to covid - prevention (vaccine) or cure (treating the symptoms).
SAR is tackling the latter and the grant is to set up a trial to help them prove it.
It will take the UK 6 months to distribute the vaccine to everyone that wants it (unbelievably some do not).
Some countries will take 2 years to cover their populations - so any medication that alleviates symptoms has a market.
There are other areas of medicine which have similar symptoms, so even if the covid market is short lived there will be other sufferers of immune system disorders who will benefit once we have clear evidence that this works.
As has been pointed out, there are a handful of other products in SARs portfolio which have the potential to dwarf the covid offering, and which will make this company a target for takeover. A covid product would hasten the journey, but we will get there regardless.

What is the target market for the report - potential customers or investors?

Take this scenario: SP at 0.4p, many have sell orders at 5p - nice if it gets there.
Drilling starts, sp slowly rises to 0.81p. Suddenly TH in Oz, 10:1 consolidation under way.
London opens at 8.1p, sell orders triggered if below 8.1p.
MMs snap up all the triggered sells at 4p,5p,6p,7p,8p and stifle the markets by sitting on them for a few hours while sp levels at say 5.5p, waiting for more weak investors to jump ship. After lunch they offer their stash at 6.2-7.2p all afternoon until sold out. Some day traders will make money, but the dice are loaded in MMs favour as they control liquidity.
The sp usually ends the day lower than the consolidation price. Those caught out by automated sell orders or through sheer panic selling try to buy back but when they dumped millions in one go they can now only buy back in the 100k's.
Consolidation is no good for the PI (and DW should know, as he is the biggest PI holder.)

Ncain, if you invest £50 to get £5000 does it really matter how many shares yo need to hold? 100 or 100k, so what?
Once the big money starts rolling in, I'm hoping that the company will buy-back cheap shares with cash surplus to its exploration budget. We shall see. On the other hand they could sell up completely for a few billion, and we can all go electric.

Probably anticipating a bumper output in November results, with decent margin to cover that 14% increase in cashew plant investment.